Novavax’s Ebola vaccine has been shown to be highly effective in a Phase I trial.
The study tested the drug in conjunction with the company’s Matrix-M adjuvant in 230 healthy adults. It was found to be “highly immunogenic” at all dose levels and well tolerated.
“These data, together with two positive challenge studies in non-human primates, suggest that the Ebola GP Vaccine would be protective in humans,” says Gregory Glenn, Novavax’s senior vice president of research and development.
The fact that the vaccine was effective at low doses could also allow for dose-sparing.
Although these results are impressive, Novavax is far from the only company developing an Ebola vaccine, and many have already passed the Phase I stage.
A vaccine from Janssen and Bavarian Nordic began Phase II trials last week, Merck and NewLink’s offering reached Phase II/III development in April, and GSK’s drug has been trialled in one of the most-affected countries, Liberia.
However, not all results have been positive. Earlier this month, Tekmira announced it would suspend development of its vaccines after data indicated that it was unlikely to hit Phase II efficacy targets.